From Large to Small Cytokine Receptor Antagonists
SLAS Discovery : Advancing Life Sciences R & D
|October 6, 2025
Summary
Biological drugs transformed disease treatment, but small molecule cytokine antagonists offer improved delivery and lower costs. Advances enable new small molecule drugs for targets like TSLP and TL1A.
Area of Science:
- Drug discovery and development
- Immunology and inflammation
- Medicinal chemistry
Background:
- Biological drugs have revolutionized treatments for oncology and autoimmune diseases by targeting extracellular cytokines.
- Limitations of biologics include poor bioavailability, tissue penetration, intracellular access, and high manufacturing costs.
- These limitations drive the development of small molecule drugs to match biologic efficacy with improved delivery and cost-effectiveness.
Purpose of the Study:
- To review trends in biological and small molecule cytokine drug discovery.
- To highlight key learnings from successful TNFα and IL-17 antagonist development.
- To discuss future directions and emerging modalities in cytokine drug discovery.
Main Methods:
- Review of general trends in biological and small molecule cytokine drug discovery.
- Analysis of case studies involving Tumor Necrosis Factor-alpha (TNFα) and Interleukin-17 (IL-17) antagonists.
- Speculation on future drug discovery landscape based on current advances.
Main Results:
- Biological drugs have successfully validated numerous cytokine targets.
- Significant progress in structural biology, computational modeling, and medicinal chemistry has enabled small molecule cytokine modulator development.
- Small molecule drugs are progressing into clinical development for various cytokine targets.
Conclusions:
- Small molecule cytokine antagonists offer a promising alternative to biologics, addressing limitations in delivery and cost.
- Future drug discovery will likely see small molecules targeting cytokines such as Thymic Stromal Lymphopoietin (TSLP) and Cytokine Ligand TL1A (TL1A).
- Novel modalities like extracellular degraders and next-generation biologics will further shape the field.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
9.4K
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.5K
Related Concept Videos
01:15Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K
01:20The JAK-STAT Signaling Pathway
12.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.0K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
01:22Amplifying Signals via Enzymatic Cascade
17.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
17.3K
01:26Signal Transduction: Overview
11.4K
Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Typically, signal transduction involves three...
11.4K
01:28Drug-Receptor Interaction: Antagonist
4.8K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.8K